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Abstract 
 
Excitotoxicity plays a key role during insults to the developing brain such as neonatal 
encephalopathy, stroke and encephalopathy of prematurity. Such insults affect many 
thousands of infants each year. Excitotoxicity causes frank lesions due to cell death and 
gliosis and disturbs normal developmental process, leading to deficits in learning, memory 
and social integration that persist into adulthood. Understanding the processes underlying 
the acute effects of excitotoxicity and its persistence during brain maturation provides an 
opportunity to identify mechanistic or diagnostic biomarkers, thus enabling and designing 
possible therapies. We applied mass spectrometry to provide metabolic profiles of brain 
tissue and plasma over time following an excitotoxic lesion (intracerebral ibotenate) to the 
neonatal (P5) mouse brain.  We found no differences between the plasma from control (PBS 
injected) and excitotoxic (ibotenate injected) groups across time (P8, P9, P10, P30). In the 
brain, we found that variations in amino acids (arginine, glutamine, phenylananine, proline) 
and glycerophospholipids were sustaining acute and delayed (tertiary) responses to injury. 
In particular, the effects of excitotoxic lesion on the normal profile of development was linked 
to alterations in a fingerprint of glycerophospolipids and amino acids. Specifically, we 
identified increases in the amino acids Glutamine, Proline, Serine, Threonine, Tryptophan, 
Valine and the sphingolipid SM C26:1 and decreases in the glycerophospholipds: 
arachidonic acid containing phosphatidylcholines (PC aa C30:2) and (PC aa C32:3). This 
study demonstrates that metabolic profiling is a useful approach to identify acute and tertiary 
effects in an excitotoxic lesion model generating a short list of targets with future potential in 
the hunt for identification, stratification and possibly therapy. 
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Introduction 
Excitotoxicity plays a key role in insults to the developing brain such as neonatal 
encephalopathy [1, 2], stroke [3, 4], encephalopathy of prematurity [5, 6] and traumatic brain 
injury [7]. Many thousands of infants suffer from these injuries every year in developed 
countries alone. Due to acute effects, such as cell death, and subsequent disturbances to 
normal development they are a leading cause of deficits in learning, memory and social 
integration that persist into adulthood [8-10]. During excitotoxicity, the excessive activation of 
glutamate receptors, (particularly N-methyl-D-aspartate (NMDA) receptors) leads to vast 
calcium influx, leading to cellular membrane damage and leakage of reactive oxygen 
species from mitochondria, inducing neural cell death and subsequent loss of neurites and 
connectivity [11-13]. However, the indiscriminate targeting of NMDA receptors induces 
localized neuronal death and behavioral deficits in adulthood [14, 15] as well as massive and 
diffuse neuronal death in the developing brain [16, 17] due to their crucial developmental 
and homeostatic functions. Preventing excitotoxic injury without directly interfering with 
NMDA receptors is therefore an appealing therapeutic strategy. Furthermore, lesions 
associated with excitotoxicity causes persisting micro- and astrogliosis, and this and other 
persisting processes may also represent viable neurotherapeutic targets [18]. A relatively 
novel approach in the search for therapeutic targets is metabolic phenotyping. Metabolites 
represent the functional endpoints of gene and protein expression and are also known as 
important modulators of cell signaling and cell survival. As such, metabolic phenotyping can 
be considered to encompass the overall physiologic status of an organism by capturing 
global biochemical events by assaying many hundreds of small molecules in cells, tissues 
and organs. This approach has been applied for acute injury profiling, and in the developing 
brain it is well known that hypoxia-ischemia induces major changes in metabolism. In 1984, 
Silverstein et. al. described the effects on monoamine metabolism in infants diagnosed with 
hypoxic-ischemic encephalopathy [19]. This work was extended in an experimental setting in 
fetal monkeys subjected to perinatal hypoxic insult [20] and changes in arachidonic acid 
metabolites was reported in 1989 in the fetal rabbit following brain hypoxia [21]. It took 
several decades until the importance of these metabolites was discovered [22] and recently, 
the effects (and altered levels) of endocannabinoids under ischemic and excitotoxic 
conditions has become of interest [23, 24].More recently, the use of fluid metabolic 
phenotyping has been applied to clinical samples following perinatal brain injury for 
biomarkers discovery [25, 26], and improving our knowledge of injury specific and temporal 
components of the metabolic profile will improve our interpretation thereof. 
 
We undertook a comprehensive analysis of the metabolic phenotype to both confirm and 
expand our knowledge about the expected mode of action of excitotoxicity. We hoped to 
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possibly pinpoint pathways outside those identified in non- metabolic phenotyping 
approaches or non-pediatric based analyses that could lead to the identification of new 
therapeutic targets [27]. Our hypothesis is that we that we could use metabolic phenotyping 
screening and the associated multivariate biostatistical analysis to provide new information 
on the effects of injury on and between multiple metabolites across time. We studied the 
well-validated and characterized excitotoxic lesion in the postnatal day (P) 5 mouse [28-30]. 
The lesion size following ibotenate injection is maximal by 24 hours, and remains stable 
for at least the following 4 weeks [28, 29]. The initial injury involves the death of 
neurons and astrocytes across all cortical and subcortical layers, and the almost 
immediate infiltration of microglia [28]. Although microglial and astrocyte number within 
the lesion return to normal (although the phenotype is unknown) there is a persistent 
injury to the periventricular white matter [28]. In this excitotoxic model we characterized 
the metabolic fingerprint occurring within the lesion and plasma at 4 time points, from the 
acute phase into young adulthood. We found that the excitotoxic lesion caused a substantial 
change away from profile observed in the control, PBS only injected group. A handful of 
metabolites related to amino acids and lipids were observed to be altered by the excitotoxic 
lesion. 
  
Blaise et al., Metabolic Characterization of Perinatal Excitotoxic Brain Lesion 
 5 
Materials and Methods:  
Experimental protocols were approved by the Bichat and Robert Debré Hospital ethics 
committee (#2011-14/646-048) and all experiments adhered to the European Union 
Guidelines for the Care and Use of Animals. In vivo procedures were typically carried out 
between 10am and 1pm (light phase 7am-7pm daily); all animals were monitored daily 
during experimentation. Each experimental unit corresponds to a single animal, with groups 
spread between and across litters. Animals were housed (Plexiglas cages 30x18x15cm) 
together with littermates and their dam from birth to P20 and weaned into single sex groups 
at P21.  Cages were supplied with wood-chip bedding and shredded paper for nesting 
(Pharmaserv, France) and animals had access to standard chow and water ad libitum. 
 
 
Animals and drugs 
Male and female Swiss pups (Iffa Credo, L’Abresle, France) were used for in vivo 
experiments. Ibotenate was purchased from Sigma (St-Louis, MO, USA). Ibotenate was 
diluted in 1x phosphate buffered saline (PBS) containing 0.01% acetic acid. 
 
Neonatal excitotoxic brain lesion and sample collection 
We induced excitotoxic brain lesions by injecting ibotenate into the developing mouse 
neopallial parenchyma on P5 as previously described [2, 31, 32].  In brief, using a 
stereotactic frame a 26 g syringe was inserted under the external surface of the scalp, 2 mm 
from the midline in the lateral medial plane and 3 mm from the junction between the sagittal 
and lamboid sutures in the rostro-caudal plane. One 1 μl bolus of ibotenate (5 ng/μl in 0.01% 
Acetic acid in 1x PBS) was administered at 2 um depth (periventricular white matter 
placement), the needle was withdrawn 1 μm (cortical placement) and a second 1 μl bolus 
was administered. The needle was held in place for 20 seconds following the injections. 
Animals were euthanized by decapitation 24 (P6), 48 (P7), 72 (P8), 120 hours (P10) and 25 
days (P30) after the injury. Blood was collected at decapitation using capillary tubes and 
plasma separated via centrifugation. The brain region corresponding to the site of injection 
was dissected out, and blood and plasma were stored at -80°C until further preparation as 
described below. Specifically, the area of the excitotoxic lesion was dissected by excising an 
area of 2mm wide and 2 mm thick of the whole depth of the cortex and underlying 
subcortical white matter from the injection site at each age. Although the necessity to take 
the entire lesion area for analysis precluded analysis of lesion size, animals performed in 
parallel for a separate study had the expected lesion size for this highly reproducible model 
[28, 33-35]. Each treatment group comprises 7 to 10 animals. 
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Sample preparation 
Frozen brain samples were weighted into 2 ml Precellys tubes (Peqlab Biotechnologie 
GmbH, Erlangen, Germany) equipped with ceramic beads. Homogenates were prepared by 
adding ethanol/10 mM phosphate buffer (85/15) solvent mixtures to the tissue sample, ratio 
3:1 (v/w). The Precellys-24 homogeniser (Peqlab Biotechnologie GmbH, Erlangen, 
Germany) uses a figure-eight motion to rapidly gyrate beads to grind up to 24 samples 
temperature controlled (0-4°C) at once with the following program: 3 cycles of 30 s at a 
frequency of 5800 rpm with a 25 s pause between cycles. Homogenates and plasma 
samples were centrifuged at 18000g at 2°C for 5 min, the resulting supernatant was pipetted 
into a cryovial (1.5 ml, Biozym GmbH, Oldendorf, Germany) and analysed immediately to 
avoid degradation of the analytes. 
 
Analytical procedures 
The flow injection analysis (FIA-MS/MS) based platform was employed for the simultaneous 
quantification of a broad range of endogenous intermediates namely acylcarnitines, amino 
acids, sphingomyelins, glycerophospholipids. A chromatographic step (LC-MS/MS) was 
applied for the additional quantification of series of amino acids and biogenic amines, small 
organic acids and other members from the energy metabolism pathway, oxysterols and 
eicosanoids Analytical protocols can be found in Urban et. al. [36] and are validated 
according to the FDA bioanalytical method validation recommendation for industry [37]. 
Samples were randomized within and across the two analytical batches. All pre- and post-
analytical procedures were performed by analysts blinded to the experimental groups. In 
total, 215 unique compounds were quantified. Analytes that did not meet quality control 
criteria or that were not detected in at approximately >70% of the samples were not selected 
for further analyses resulting in 182 unique metabolites retained for analysis and reporting. A 
list of excluded compounds for the plasma analysis was OH-Kynurenine, PEA, Nitro-Tyr, 
Dopamine, OH-Pro, and for the brain analysis was OH-Kynurine, Nito-Tyr, OH-Pro, 9-
HODE, 12(15)-EpETE, 15S-HpETE, 5S-HpETE, LTD4, 8-iso PGF2, PEP, alpha-KGA, Tetr-
P, 22ROHC, 20aOHC, 22SOHC, THC, 7aOHC, Desmosterol, 7DHC, Cholesternoe, 
24DHLan. A quantitative (or semi quantitative) targeted approach was employed resulting in 
the generation of normalized concentration value for specific compound. Data preprocessing 
is therefore limited to two activities: zero values imputation and data transformation. A 
detailed list of all metabolites that are considered for interpretation is given in Supplementary 
Table 1. In short, it is comprised of 25 acylcarnitines, 93 lipids derivatives (11 
sphingomyelins, 72 glycerophosphatidylcholines and 10 lysophospholipids), 21 amino acids, 
11 biogenic amines, 12 eicosanoids and prostaglandins, 13 oxidised products of cholesterol 
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(oxysterols) and 6 members of the energy metabolism pathway. Where the limit of detection 
was not reached for a given variable then the value was set to 0 and columns or rows 
comprising of only zeros were removed prior to analysis. Data were formatted as a data 
matrix comprising 80 lines (samples) and 147 columns (metabolic variables).  
 
Multivariate statistical analysis  
Data were pareto scaled before analysis. Unsupervised principal component analysis was 
run in both sub-populations to check sample homogeneity and exclude outliers.  An O-PLS 
analysis (orthogonal projections to latent structures) [38, 39] was carried out to investigate 
the information shared by the mass spectral matrix X and the descriptive variable matrix Y. 
Spectra are visualized in scores plots and the metabolic variations sustaining the 
discrimination are presented in loadings plots.  The O-PLS analysis was run to discriminate 
populations by regressing a supplementary data matrix Y, containing information about the 
membership of samples to each group. Model performances were assessed by goodness-
of-fit parameters R2 and Q2, related, respectively, to the explained and predicted variance. 
We performed model validation by resampling the model 1000 times under the null 
hypothesis (i.e. by random permutation).  Observed and predicted Y matrixes were 
computed using an O-PLS-DA MATLAB routine developed in the lab. Receiver Operating 
Characteristic (ROC) curves were plotted using MATLAB. These represent the true positive 
rate as a function of the false positive rate and determine the best threshold for a given test 
to define the membership of a class. The diagonal stands for random prediction, whereas 
the more the curve moves to the top left corner, the better the prediction ability of the model 
is. Scaled to maximum aligned and reduced trajectories (SMART) analysis [40] was used to 
cancel out the differences between the metabolic starting positions of the different groups 
and evaluate the metabolic trajectories with respect to time. O-PLS-VIPs (variable influence 
on projection) allow the identification of variables that are important in the multivariate 
signature discriminating the 2 groups. They were computed with a MATLAB routine based 
on the published algorithm [41].   VIP values above 2 were chosen as variables of interest.  
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Results:  
Our first analysis evaluated if metabolic phenotyping could discriminate between samples 
from brain tissues from mice injected with PBS (controls) and the samples of brain injected 
with ibotonate (model of focal lesion induced via excitotoxicity). Subsequent to this, as a 
post-hoc analysis, we then investigated the metabolic changes occurring between the 
different time points to monitor the metabolic evolution induced by the excitotoxic lesion. 
Between group discrimination analysis 
Brain and plasma samples were analyzed with the aim of identifying metabolic differences 
between PBS injected (control) animals and ibotenate injected (lesioned) animals and 
between 7-10 samples were generated for each data point. Plasma samples did not exhibit 
significant metabolic variations. However, the PBS and Ibotenate brain samples could be 
robustly separated via a computed single predictive component from the 1+7 component O-
PLS analysis (Figure 1A). This is a dimension reduction technique that allows regression 
analysis where we know that some of our independent variable (metabolites) can co-vary. 
Goodness-of-fit parameters of the model were high, with an explanation capacity R2 of 0.830 
and a prediction capacity Q2 of 0.677 (maximum = 1).  
We used two strategies to test the strength of our model to explain the difference between 
the control and ibotenate groups in this study, which was exploratory for the utility of 
metabolic phenotyping to discriminate these 2 groups. First we used resampling under the 
null hypothesis. We identified, in comparison to our real data, that there was a clear 
decrease of the goodness-of-fit parameters (Figure 1B) when the model is based on a 
random class information matrix (decrease in R2 and Q2 with the correlation between the 
original and permuted sample identifications). An empirical p-value was computed to 
measure the number of random models outperforming our initial real data model. The p-
value value was 0, demonstrating that no random model achieved better quality coefficients 
than the original real data model, thus validating its robustness. Secondly, discrimination 
capacity was assessed using a cross-validated receiver-operating characteristic (ROC: 
Figure 1C) showing an area under the curve (AUC) of 0.98 further validating the strength of 
the model to explain the difference between the control and ibotenate groups. 
To identify statistically significant variation of a single metabolite that would explain the 
observed difference we used a univariate statistical analysis (analysis of variance) coupled 
with multiple hypotheses testing correction (Benjamini-Yekutieli correction). This failed to 
identify a single discriminatory metabolite. Instead, we implemented variable importance on 
projection (VIP) for O-PLS to identify, in a multivariate way, the metabolic changes that were 
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important to explain the difference between the groups. VIPs were only derived from the 
predictive component of the model. Variables exhibiting a stringent O-PLS-VIP (above 2[41]) 
were kept and are shown in Figure 1D. We observed an increase of many amino acids 
(glutamine, proline, serine, threonine, tryptophan, valine) and the sphingolipid SM C26:1 
(sphyingomyelin, 26 carbon residues, 1 double bond) associated with the ibotenate lesion 
compared with PBS and a decrease in glycerophospholipids (arachidonic acid-containing 
phosphatidylcholines, PC aa 30:2 & PC aa C32:3).  
 
Time-series analysis 
To evaluate the metabolic changes associated with time after the injection of either PBS or 
ibotenate within the 2 groups we ran a time-series analysis. SMART analysis was performed 
(Figure 2A), showing 2 different metabolic trajectories (after PBS injection in black or 
ibotenate injection in red) across our time points (1, 2, 3, 5 and 25 days after the injury). 
Note that the 2 trajectories do not have the same starting point because we do not have a 0-
time sample (pre-injury) in the analysis and the first samples were collected after exposure. 
The SMART analysis produced a first component that is associated with 69% of the 
explained variance and a second component associated with 21% of variance. It drops 
below 5% for the third principal component. Metabolites and their direction of change 
collectively responsible for the variance within the 1st and 2nd principal components were 
identified (Figure 2B) and the values for each metabolite for each time point are presented in 
Figure 3.  It is worth noting that the model captures both the direction and magnitude of 
change and as such a metabolite moving in opposing directions over time or due to 
treatment can appear in two principal components.  
We considered how the data changes with respect to time within the PBS and Ibotenate 
groups. Initially, PBS and ibotenate samples have different positions along the 1st 
component, but similar positions along the 2nd component. Across time points, the 2 
metabolic trajectories have similar shapes (moving right to left within PC1 and top to bottom 
within PC2). However, the PBS trajectory has a greater range in the metabolic space for 
both PC1 and PC2. After 25 days, the 2 groups have close positions along the 1st 
component but clearly different positions along the 2nd component. Furthermore, the final 
position of the ibotenate signal along the 2nd component is equivalent to its initial position. It 
thus seems that injury effects are translated in the metabolic space along the 1st component 
(variations in acylcarnitine, arginine, glutamine, phenylalanine, proline, serine, tyrosine, 
valine, glycerophospholipids and sphingolipids) but that this difference is corrected after 25 
days of development. However, in the PBS group only another metabolic difference appears 
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(variations in arginine, glutamine, valine and glycerophospholipids) showing a clear change 
over time in the 2nd component. This component was associated with an up-regulation of 
arginine, glutamine and glycerophospholipids and a down-regulation in valine.  
Blaise et al., Metabolic Characterization of Perinatal Excitotoxic Brain Lesion 
 11 
Discussion 
In the present study, a mass spectrometry based metabolic phenotyping strategy was 
applied to evaluate the impact over time of an excitotoxic lesion in the developing mouse 
brain. We used an O-PLS-based analysis to discriminate between the two groups at the 4 
timepoints (1+7 components, R2=0.830, Q2=0.677). From this analysis, we observed 
changes in concentrations of the amino acid and lipid biochemical classes were associated 
with ibotenate injury. We also performed a time-series analysis (SMART), generating a 
model in which the first two principal components accounted for 90% of the data variance 
(69% and 21% respectively). Investigating time dependent changes was not the primary 
goal of this study. However, it is noted that early time points were more associated with 
changes in the 1st component (including serine and sphingolipid SM C26:1), and the later 
(tertiary) time points more associated with changes in the 2nd component (including the 
glycerophospholipids [arachidonic acid-containing phosphatidylcholines] PC aa 36:3)   
 
In comparison to NMR (nuclear magnetic resonance spectroscopy), mass-spectrometry 
based strategies are justified for several reasons. The small amount of immature and/or 
specific brain regions in rodent models typically requires sample pooling for analysis via 
NMR. However, mass spectrometry can be performed on single animal samples, 
maintaining the optimal balance between statistical power and number of experimental 
animals. In combination with the improved metabolite discrimination, the modularity of MS-
based platforms allows a wider coverage of not only the metabolome but also of specific 
class of metabolites by including their members present a lower concentration. In the scope 
of this study, our targeted MS-based metabolic phenotyping enabled the simultaneous 
coverage of pathways that were hypothesized to represent intermediary metabolism 
involved in excitotoxic injury [42], namely phospholipids, sphingomyelins, eicosanoids, 
oxidised products of cholesterol, acylcarnitines and several members of the TCA cycle. In 
addition, the whole range of amino acids and several biogenic amines (e.g., serotonin, 
dopamine) central to brain research were also included. 
 
Our O-PLS analysis comparing control and excitotoxic lesion metabolites produced a robust 
model that we validated to explain the vast majority of variance in the data. A limitation of the 
model validation is that we did not have access to an independent data set. The benefits of 
the O-PLS analysis are its supervised nature, allowing a focus on the specific effects of the 
study. However, the model displays information along predictive and orthogonal axes that 
both should be investigated. Although we were not able to identify a single metabolite 
responsible for a significant amount of variation in this model we did identify a fingerprint of 9 
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metabolites belonging to the amino acid, glycerophospholipid and sphingolipid families. It is 
of course likely that change in these key factors is due to metabolic and cellular dysfunction 
including changes in the cellular composition of the injured brain.  
Regarding the cellular composition of the brain and how this corresponds to the metabolic 
results, we have previously characterized this model at 4h, 8h, and 1d, 2d, 3d, 4d, 5d and 
20d post lesion [2, 28, 43]. We observed that neuronal death is occurring at +12 hours after 
ibotenate, and becomes maximal at +24 hours but that there is no more neuronal loss at +48 
hours. Microglia increase substantially in number between +2 and +4 hours, and their 
numbers remain elevated at +5 days.  Regarding astrocytes, we observe that there is an 
initial reduction in number to a nadir at +24 hours and that numbers reach above control by 
+48 hours and normalize between +5 and +25 days.  We have previously demonstrated that 
microglia are the chief mediators of injury in this model, using pharmacological and antibody 
mediated approaches [43]. Regarding the role of altered amino acids as revealed by our 
current analysis, microglial activation dynamics have been studied in depth with 
metabolomics approaches and these reveal specialized expression patterns of amino 
acids tied to activation states [44]. However, specific links cannot be made between 
amino acid changes in our data, given the heterogeneity in the cell types in this lesion. 
Nevertheless, we can mention that high levels of branch chain animal acids such as 
valine favor astrocyte-dependent neurotoxicity by NMDA receptor activation and influence 
gene expression and immune properties of microglial cells [45].  In addition, would could 
associate the increases in glutamine with the higher numbers of astrocytes within the lesion, 
as this amino acid is enriched in these glial cells [46]. Regarding lipid class metabolites, the 
membranes of neural cells are composed of glycerophospholipids, sphingolipids, and 
assorted proteins asymmetrically distributed between the two lipid bilayers. 
Glycerophospholipids consist of four primary phospholipids; phosphatidylcholine (PC), 
phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol.  
Glycerophospholipids and sphingolipids play a role in the structural integrity of these neural 
membranes. Also, neuronal membrane phospholipids are important reservoirs for second 
messengers, such as prostaglandins, eicosanoids, platelet activating factor and 
diacylglycerol. As such, we could suppose that there is a plausible link between increases in 
glial cell numbers and neuronal death profiles and the observations of metabolites. 
Supporting a facet of this, is that, a recent study reports that arachidonic acid-containing 
phosphatidylcholines (PC aa metabolites) are enriched in microglia, specifically in the spinal 
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cord microglia following peripheral nerve injury  [47]. In addition, the death of 
oligodendrocytes and the formation of a white matter cyst is a key component of this model 
[35]. As such, changes in sphingolipids are logical as sphingolipids are found in animal cell 
membranes, especially in the membranous myelin sheath which surrounds some nerve cell 
axons.  
There are also previous reports on the effects of excitotoxicity on brain metabolites. 
Specifically, He et al. [49] identified variations in ceramide metabolism in a rat model of 
hippocampal injury, induced by excitotoxic lesion using kainate acid. We observed variations 
in amino acids (and in particularly serine) and sphingolipid metabolism that can be 
connected to ceramide metabolism. However, in our analysis changes in these metabolites 
did not reach the level of statistical significance 
 
Using the SMART analysis to assess the metabolic trajectories over time, at the first-time 
point (+24 h) we noted there was considerable difference in the 1st component metabolites 
(such as C9 acylcarnitine and the sphingolipid SM C26:1). We speculate this variance is due 
to the significant excitotoxicity induced changes in the brain tissue at this first time point of 
analysis, namely cell death and gliosis [28]. Also, at the latest time point, 25 days after the 
lesion (in the tertiary phase), it has previously been observed in this model that gliosis has 
subsided but that there remains a considerable lesion in the periventricular white matter. At 
this tertiary time point the greatest variation identified by the SMART analysis was due to 
increases in metabolites from the 2nd component, such as the glycerophopholipids (C36:3). 
A disturbance to normal developmental processes are considered a major contributor to 
brain damage observed in preterm born infants, the encephalopathy of prematurity [48]. We 
speculate that this change in PC2 represents a developmental disturbance caused by the 
excitotoxic lesion. Although the study of normal development was outside the planned scope 
of this study, it is of interest to speculate that the PC2 related changes in the PBS (control) 
group likely reflect normal changes in cellular composition and cellular maturation. 
 
Metabolic phenotyping has been shown to be useful in discriminating in human cohorts 
between variables as diverse as aging and viral infection, see [27]. Fluid based 
metabolomics is an increasingly popular area of research in perinatal medicine, with studies 
related to neonatal encephalopathy and chorioamnionitis [26, 50-52]. Attempts have even 
been made to correlate metabolic changes with neuropathology in a sheep model of 
inflammation driven perinatal brain injury [53]. This sheep study also demonstrated changes 
in the mid-term caused by injury, out to 10 days post-insult, although this injury is more 
severe and it is likely to have also persisted out into the tertiary phase as in this study We 
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did not observe the multitude of changes in the metabolic phenotypes as observed in the 
sheep study and it is likely due to the more moderate nature of our injury that explains the 
limited effects in this study. 
 
Analysis of injury in this model revealed that at least by 24 hours that there is a 
compartmentalization of response to injury in this model (no plasma changes). We can 
assume that there is little systemic-central crosstalk as cell death and gliosis peak at 48 
hours onwards in this model and as such that the metabolic changes are driven primarily by 
the events within the brain. This is an interesting facet of the model and will allow us to 
further refine brain specific metabolic phenotypes for biomarker discovery. 
In conclusion, this is the first assessment of the metabolic phenotype in a model of 
perinatal excitotoxicity including an analysis of the effects into young adulthood. We 
found that a short list of amino acids and glycerophospholipids explained the effects of 
the excitotoxic lesion. Furthermore, we found that there were differences in the normal 
processes of development that could be visualized with this approach. These targets 
may be useful starting points for studies into acute or tertiary phase biomarkers 
specifically for excitotoxic processes. 
  
Blaise et al., Metabolic Characterization of Perinatal Excitotoxic Brain Lesion 
 15 
References 
1. Mesples, B., et al., Pathophysiology of neonatal brain lesions: lessons from animal 
models of excitotoxicity. Acta Paediatrica, 2005. 94(2): p. 185-90. 
2. Marret, S., et al., Effect of ibotenate on brain development: an excitotoxic mouse 
model of microgyria and posthypoxic-like lesions. Journal of neuropathology and 
experimental neurology, 1995. 54(3): p. 358-70. 
3. Lee, J.M., G.J. Zipfel, and D.W. Choi, The changing landscape of ischaemic brain 
injury mechanisms. Nature, 1999. 399(6738 Suppl): p. A7-14. 
4. Wahlestedt, C., et al., Antisense oligodeoxynucleotides to NMDA-R1 receptor 
channel protect cortical neurons from excitotoxicity and reduce focal ischaemic 
infarctions. Nature, 1993. 363(6426): p. 260-3. 
5. Burd, I., et al., Excitotoxicity as a Common Mechanism for Fetal Neuronal Injury with 
Hypoxia and Intrauterine Inflammation. Adv Pharmacol, 2016. 76: p. 85-101. 
6. Johnston, M.V., Excitotoxicity in perinatal brain injury. Brain Pathol, 2005. 15(3): p. 
234-40. 
7. Palmer, A.M., et al., Traumatic brain injury-induced excitotoxicity assessed in a 
controlled cortical impact model. J Neurochem, 1993. 61(6): p. 2015-24. 
8. Costeloe, K.L., et al., Short term outcomes after extreme preterm birth in England: 
comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). BMJ, 2012. 
345: p. e7976. 
9. Ewing-Cobbs, L., et al., Late intellectual and academic outcomes following traumatic 
brain injury sustained during early childhood. J Neurosurg, 2006. 105(4 Suppl): p. 
287-96. 
10. Lee, J., et al., Predictors of outcome in perinatal arterial stroke: a population-based 
study. Annals of Neurology, 2005. 58(2): p. 303-8. 
11. Choi, D.W., Glutamate neurotoxicity and diseases of the nervous system. Neuron, 
1988. 1(8): p. 623-34. 
12. Coyle, J.T. and P. Puttfarcken, Oxidative stress, glutamate, and neurodegenerative 
disorders. Science, 1993. 262(5134): p. 689-95. 
13. Lipton, S.A. and P.A. Rosenberg, Excitatory amino acids as a final common pathway 
for neurologic disorders. N Engl J Med, 1994. 330(9): p. 613-22. 
14. Olney, J.W., et al., NMDA antagonist neurotoxicity: mechanism and prevention. 
Science, 1991. 254(5037): p. 1515-8. 
15. Olney, J.W., J. Labruyere, and M.T. Price, Pathological changes induced in 
cerebrocortical neurons by phencyclidine and related drugs. Science, 1989. 
244(4910): p. 1360-2. 
16. Jevtovic-Todorovic, V., et al., Early exposure to common anesthetic agents causes 
widespread neurodegeneration in the developing rat brain and persistent learning 
deficits. J Neurosci, 2003. 23(3): p. 876-82. 
17. Ikonomidou, C., et al., Blockade of NMDA receptors and apoptotic 
neurodegeneration in the developing brain. Science, 1999. 283(5398): p. 70-4. 
18. Fleiss, B. and P. Gressens, Tertiary mechanisms of brain damage: a new hope for 
treatment of cerebral palsy? Lancet Neurol, 2012. 11(6): p. 556-66. 
19. Silverstein, F. and M.V. Johnston, Effects of hypoxia-ischemia on monoamine 
metabolism in the immature brain. Ann Neurol, 1984. 15(4): p. 342-347. 
20. Binienda, Z., et al., Acute effects of perinatal hypoxic insult on concentrations of 
dopamine, serotonin, and metabolites in fetal monkey brain. Int J Dev Neurosci, 
1994. 12(2): p. 127-131. 
21. Yavin, E., et al., Ischemia stress and arachidonic acid metabolites in the fetal brain. 
Ann N Y Acad Sci, 1989. 559: p. 248-58. 
22. Palomba, L., L. Cerioni, and O. Cantoni, Arachidonic acid inhibits neuronal nitric 
oxide synthase elicited by proinflammatory stimuli and promotes astrocyte survival 
with both exogenous and endogenous peroxynitrite via different mechanisms. J 
Neurosci Res, 2010. 88(11): p. 2459-2468. 
Blaise et al., Metabolic Characterization of Perinatal Excitotoxic Brain Lesion 
 16 
23. Landucci, E., et al., Involvement of endocannabinoid signaling in the neuroprotective 
effects of subtype 1 metabotropic glutamate receptor antagonists in models of 
cerebral ischemia. Int Rev Neurobiol, 2009. 85: p. 337-350. 
24. Shouman, B., et al., Endocannabinoids potently protect the newborn brain against 
AMPA-kainate receptor-mediated excitotoxic damage. Br J Pharmacol, 2006. 148(4): 
p. 442-451. 
25. Fattuoni, C., et al., Perinatal Asphyxia: A Review from a Metabolomics Perspective. 
Molecules, 2015. 20(4): p. 7000-7016. 
26. Walsh, B.H., et al., The metabolomic profile of umbilical cord blood in neonatal 
hypoxic ischaemic encephalopathy. PLoS One, 2012. 7(12): p. e50520. 
27. Kaddurah-Daouk, R., B.S. Kristal, and R.M. Weinshilboum, Metabolomics: a global 
biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol, 
2008. 48: p. 653-83. 
28. Tahraoui, S.L., et al., Central role of microglia in neonatal excitotoxic lesions of the 
murine periventricular white matter. Brain pathology, 2001. 11(1): p. 56-71. 
29. Husson, I., et al., Melatoninergic neuroprotection of the murine periventricular white 
matter against neonatal excitotoxic challenge. Annals of neurology, 2002. 51(1): p. 
82-92. 
30. Haldipur, P., et al., HIP/PAP prevents excitotoxic neuronal death and promotes 
plasticity. Ann Clin Transl Neurol, 2014. 1(10): p. 739-54. 
31. Carlsson, Y., et al., Genetic inhibition of caspase-2 reduces hypoxic-ischemic and 
excitotoxic neonatal brain injury. Annals of Neurology, 2011. 70(5): p. 781-9. 
32. Degos, V., et al., Neuroprotective effects of dexmedetomidine against glutamate 
agonist-induced neuronal cell death are related to increased astrocyte brain-derived 
neurotrophic factor expression. Anesthesiology, 2013. 118(5): p. 1123-32. 
33. Bouslama, M., et al., Melatonin prevents learning disorders in brain-lesioned 
newborn mice. Neuroscience, 2007. 150(3): p. 712-9. 
34. Husson, I., et al., BDNF-induced white matter neuroprotection and stage-dependent 
neuronal survival following a neonatal excitotoxic challenge. Cerebral cortex, 2005. 
15(3): p. 250-61. 
35. Laudenbach, V., et al., Nociceptin/orphanin FQ exacerbates excitotoxic white-matter 
lesions in the murine neonatal brain. The Journal of clinical investigation, 2001. 
107(4): p. 457-66. 
36. Urban, M., et al., Complexity and pitfalls of mass spectrometry-based targeted 
metabolomics in brain research. Anal Biochem, 2010. 406(2): p. 124-31. 
37. FDA, C.f.D.E.a.R., Nonclinical Safety Evaluation of Pediatric Drug Products, F.a.D.A. 
(FDA), Editor. 2006: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidanc
es/ucm079247.pdf. 
38. Trygg, J., O2-PLS for qualitative and quantitative analysis in multivariate calibration. 
Chemometrics and Intelligent Laboratory Systems, 2002. 16: p. 283-293. 
39. Trygg, J. and S. Wold, Orthogonal projections to latent structures (O-PLS). 
Chemometrics and Intelligent Laboratory Systems, 2002. 16: p. 119-128. 
40. Keun, H.C., et al., Geometric trajectory analysis of metabolic responses to toxicity 
can define treatment specific profiles. Chem Res Toxicol, 2004. 17(5): p. 579-87. 
41. Galindo-Prieto, B., L. Eriksson, and J. Trygg, Variable influence on projection (VIP) 
for orthogonal projections to latent structures (OPLS). Journal of Chemometrics, 
2014. 28(8): p. 623-632. 
42. Ong, W.Y., et al., Changes in brain cholesterol metabolome after excitotoxicity. Mol 
Neurobiol, 2010. 41(2-3): p. 299-313. 
43. Dommergues, M.A., et al., Early microglial activation following neonatal excitotoxic 
brain damage in mice: a potential target for neuroprotection. Neuroscience, 2003. 
121(3): p. 619-28. 
44. Bell-Temin, H., et al., Novel Molecular Insights into Classical and Alternative 
Activation States of Microglia as Revealed by Stable Isotope Labeling by Amino 
Blaise et al., Metabolic Characterization of Perinatal Excitotoxic Brain Lesion 
 17 
Acids in Cell Culture (SILAC)-based Proteomics. Mol Cell Proteomics, 2015. 14(12): 
p. 3173-84. 
45. De Simone, R., et al., Branched-chain amino acids influence the immune properties 
of microglial cells and their responsiveness to pro-inflammatory signals. Biochim 
Biophys Acta, 2013. 1832(5): p. 650-9. 
46. Amaral, A.I., et al., A comprehensive metabolic profile of cultured astrocytes using 
isotopic transient metabolic flux analysis and C-labeled glucose. Front 
Neuroenergetics, 2011. 3: p. 5. 
47. Xu, D., et al., Increased arachidonic acid-containing phosphatidylcholine is 
associated with reactive microglia and astrocytes in the spinal cord after peripheral 
nerve injury. Sci Rep, 2016. 6: p. 26427. 
48. Volpe, J.J., The encephalopathy of prematurity--brain injury and impaired brain 
development inextricably intertwined. Semin Pediatr Neurol, 2009. 16(4): p. 167-78. 
49. He, X., et al., Expression, activity, and role of serine palmitoyltransferase in the rat 
hippocampus after kainate injury. J Neurosci Res, 2007. 85(2): p. 423-32. 
50. Beckstrom, A.C., et al., Application of comprehensive two-dimensional gas 
chromatography with time-of-flight mass spectrometry method to identify potential 
biomarkers of perinatal asphyxia in a non-human primate model. J Chromatogr A, 
2011. 1218(14): p. 1899-906. 
51. Dudzik, D., et al., LC-MS-based metabolomics identification of novel biomarkers of 
chorioamnionitis and its associated perinatal neurological damage. J Proteome Res, 
2015. 14(3): p. 1432-44. 
52. Chun, P.T., et al., Serial plasma metabolites following hypoxic-ischemic 
encephalopathy in a nonhuman primate model. Dev Neurosci, 2015. 37(2): p. 161-
71. 
53. Keller, M., et al., Inflammatory-induced hibernation in the fetus: priming of fetal sheep 
metabolism correlates with developmental brain injury. PLoS One, 2011. 6(12): p. 
e29503. 
 
  
Blaise et al., Metabolic Characterization of Perinatal Excitotoxic Brain Lesion 
 18 
Acknowledgements 
This study was supported by grants from Inserm, Université Paris Diderot, Université 
Sorbonne-Paris-Cité, Investissement d'Avenir (ANR-11-INBS-0011, NeurATRIS), ERA-NET 
Neuron (Micromet), DHU PROTECT, PremUP, Fondation de France, Fondation pour la 
Recherche sur le Cerveau, Fondation des Gueules Cassées, Roger de Spoelberch 
Foundation, Grace de Monaco Foundation, Leducq Foundation, Cerebral Palsy Alliance 
Research Foundation Australia, and the Wellcome Trust (WSCR P32674). Benjamin J. 
Blaise is supported by the Fédération pour la Recherche Médicale, the Société Française 
d’Anesthésie et Réanimation, the Académie Nationale de Médecine, the Association de 
Néonatologie de Port-Royal and the City of Lyon the Fondation Bettencourt Schueller and 
the Royal Society of Chemistry. In addition, the authors acknowledge financial support from 
the Department of Health via the National Institute for Health Research (NIHR) 
comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation 
Trust in partnership with King's College London and King’s College Hospital NHS 
Foundation Trust. The supporting bodies played no role in any aspect of study design, 
analysis, interpretation or decision to publish this data.  
 
 
 
 
  
Blaise et al., Metabolic Characterization of Perinatal Excitotoxic Brain Lesion 
 19 
 
 
 
Figure 1. (A) 1+7 component OPLS score plot discriminating PBS injected (control as plain 
black squares) and ibotenate injection (excitotoxic lesion in empty red circles) brain tissue 
samples. (B) Resampling under the null hypothesis for model validation. (C) Cross-validated 
receiver operating characteristics curve. (D) Metabolites identified by high OPLS-VIP (above 
2) as valuable for the discrimination between the 2 groups. PC = phosphatidylcholines, aa= 
arachidonic acid, C = carbon number, SM = sphingomyelin. 
 
Figure 2. (A) SMART-scaled analysis of the PBS (black) and ibotenate (red) injected 
groups. Each dot represents a time point in the analysis in both PBS and ibotenate 
trajectories. Samples were taken at day 1, 2, 3, 5 and 25-post injection. Note that the 2 
trajectories do not start on the same point because there is no pre-exposure sample. (B) 
Metabolites involved in the first and second components of the SMART model. PC = 
phosphatidylcholines, aa= arachidonic acid, C = carbon number, SM = sphingomyelin. 
 
Figure 3. Values for each of the metabolites varying in the SMART analysis. Metabolites are 
listed for each time and both treatments in arbitrary units (A.U). Values are color coded 
within each metabolite across time for PBS and Ibotenate with higher values in green and 
lower values in red.  PC = phosphatidylcholines, aa= arachidonic acid, C = carbon number, 
SM = sphingomyelin. 
 
Supplementary Table 1: A detailed list of all metabolites and raw data used for analysis 
 
 
